The Brand Name PROXYC-FT Has Generic Salt :: Piroxicam
PROXYC-FT Is From Company Emcure Priced :: Rs. 13.9
PROXYC-FT have Piroxicam is comes under Sub class Analgesics , Anti inflammatory Drugs of Main Class Musculoskeletal Disorders , Pain
Main Medicine Class:: Musculoskeletal Disorders , Pain Sub Medicine Class :: Analgesics , Anti inflammatory Drugs
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Acute gout, Rheumatic disorders, Postoperative pain, Acute musculoskeletal conditions, Juvenile idiopathic arthritis
Drug Dose ::
Adult: PO Rheumatic disorders Initial: 20 mg/day as a single dose. Maintenance: 10-30 mg in single or divided doses. Acute gout 40 mg/day for 5-7 days. Acute musculoskeletal conditions; Post-op pain Initial: 40 mg/day for 2 days. Maintenance: 20 mg/day for 1-2 wk. Juvenile idiopathic arthritis Child: >6 yr: <15 kg: 5 mg, 16-25 10 26-45 15>46 kg: 20 mg. Doses to be taken once daily.
Hypersensitivity, active peptic ulceration, porphyria, pregnancy (3rd trimester) and lactation.
Drug Precautions ::
Elderly, childn <12 yr. patients with infections, asthma, allergic disorders, haemorrhagic disorders or hypertension. impaired renal, hepatic cardiac function. monitor for signs of liver, kidney, blood eye disorders. Drug Side Effects ::
GI disturbances, peptic ulcer, GI bleeding, headache, dizziness, blurred vision, tinnitus, skin rashes and pruritus. Haematological changes and photosensitivity. Potentially Fatal: Thrombocytopaenia and acute nephropathy. Toxic epidermal necrolysis and Stevens-Johnson syndrome.
Pregnancy category ::
Drug Mode of Action ::
Piroxicam is a NSAID, belonging to the oxicam group. It inhibits prostaglandin synthesis, reduces fever by acting on the heat-regulating center of the hypothalamus, inhibits platelet-aggregating substance thromboxane A2 and reduces pain receptor sensitivity. It also exerts anti-inflammatory effect by lysosomal stabilisation, kinin and leukotriene production, alteration of chemotactic factors and neutrophil activation inhibition.
Drug Interactions ::
Increased risk of GI bleeding w/ anti-platelets and SSRIs. May exacerbate cardiac failure, reduce GFR and increase plasma glycoside levels. Increased risk of nephrotoxicity w/ ciclosporin and tacrolimus. Increased absorption w/ cimetidine. Increased risk of GI ulceration w/ corticosteroids. May interfere w/ the natriuretic action of diuretics. May displace other highly protein-bound drugs. May increase steady state plasma lithium levels. May antagonise the effect of antihypertensives. May reduce the excretion of methotrexate, leading to acute toxicity. Increased risk of convulsions w/ quinolones. May interfere w/ mifepristone-mediated termination of pregnancy. Potentially Fatal: May enhance the effect of anticoagulants (e.g. warfarin). Increased risk of serious GI events w/ aspirin and other NSAIDs.